论文部分内容阅读
目的:观察软肝合剂联合干扰素对乙型肝炎及肝纤维化的治疗作用。方法:所有观察对象随机分为治疗组(用软肝合剂联合干扰素治疗)和对照组(用干扰素治疗),观察两组间治疗前后HBV—DNA、HBeAg、肝功能、血清透明质酸(HA)、Ⅳ型胶原(Ⅳ-C)、层粘蛋白(LN)水平变化情况。结果:两药联用较对照组在HBV—DNA及HBeAg转阴率方面差异无显著性(P>0.05),治疗组天冬氨酸转氨酶(AST)、丙氨酸氨基转氨酶(ALT)下降较对照组差异有非常显著性(P<0.01),治疗组血清HA、IV—C、LN水平下降程度较对照组差异有非常显著性(P<0.01)。结论:软肝合剂联用干扰素在抗病毒方面无协同增效作用,而在保肝、抗纤维化方面有协同增效作用。
Objective: To observe the therapeutic effect of Ruangan Mixture combined with interferon on Hepatitis B and liver fibrosis. Methods: All the observation subjects were randomly divided into treatment group (treated with Ruanghui Mixture) and control group (treated with interferon). HBV-DNA, HBeAg, liver function, serum hyaluronic acid HA), type Ⅳ collagen (Ⅳ-C), laminin (LN) level changes. Results: Compared with the control group, there was no significant difference of HBV-DNA and HBeAg negative rate (P> 0.05). The AST, ALT decreased There was significant difference between the control group and the control group (P <0.01). The decrease of serum HA, IV-C and LN in the treatment group was significantly different from that in the control group (P <0.01). Conclusion: Ruangan Mixture combined with interferon has no synergistic effect on antiviral activity, but synergistic effect on liver protection and anti-fibrosis.